ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2025
Use of 18F-FDG PET in assessing response to treatment in adults with pulmonary sarcoidosis: A systematic literature review.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimSymptoms, severity and response to treatment of sarcoidosis can follow a heterogenous pattern, presenting a clinical challenge. Use of Fludeoxyglucose F18 Positron Emission Tomography (18F-FDG PET) in disease monitoring remains uncertain. We undertook a systematic literature review on the use of 18F-FDG PET in assessing response to treatment in adults with pulmonary sarcoidosis.
methodsArticles discussing 18F-FDG PET use in response to treatment in pulmonary sarcoidosis published until January 2024 were included. All article types were eligible except opinion pieces, case reports, case series of ≤10 patients and reviews.
resultsTime between baseline 18F-FDG PET and follow-up scan ranged from 2 to 6 months. Compared to clinical response, sensitivity of 18F-FDG PET in determining response to treatment ranged from 56% to 100%, with mean sensitivity of 75.3% (SD 16.0).
conclusions18F-FDG PET could be considered in monitoring response to immunosuppression in patients with pulmonary sarcoidosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.